Total Payments
$35,322
2024 Payments
$14,934
Companies
8
Transactions
33
Medicare Patients
1,177
Medicare Billing
$126,678
Payment Breakdown by Category
Consulting$28,614 (81.0%)
Research$3,200 (9.1%)
Other$1,660 (4.7%)
Travel$1,452 (4.1%)
Food & Beverage$395.97 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $28,614 | 17 | 81.0% |
| Unspecified | $3,200 | 1 | 9.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,660 | 3 | 4.7% |
| Travel and Lodging | $1,452 | 7 | 4.1% |
| Food and Beverage | $395.97 | 5 | 1.1% |
Payments by Type
General
$32,122
32 transactions
Research
$3,200
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $9,859 | 10 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $7,963 | 5 | $0 (2024) |
| Genentech, Inc. | $6,416 | 7 | $0 (2022) |
| Partner Therapeutics, Inc. | $5,010 | 7 | $0 (2024) |
| PFIZER INC. | $3,200 | 1 | $0 (2022) |
| ModernaTX, Inc. | $1,225 | 1 | $0 (2022) |
| Eli Lilly and Company | $1,200 | 1 | $0 (2021) |
| VERTEX PHARMACEUTICALS INCORPORATED | $450.00 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,934 | 14 | Regeneron Pharmaceuticals, Inc. ($9,859) |
| 2023 | $392.50 | 1 | Mallinckrodt Hospital Products Inc. ($392.50) |
| 2022 | $7,338 | 4 | PFIZER INC. ($3,200) |
| 2021 | $5,635 | 4 | Mallinckrodt Hospital Products Inc. ($2,860) |
| 2020 | $1,325 | 2 | Partner Therapeutics, Inc. ($875.00) |
| 2019 | $2,100 | 2 | Partner Therapeutics, Inc. ($2,100) |
| 2018 | $3,598 | 6 | Genentech, Inc. ($3,598) |
All Payment Transactions
33 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/06/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $4,290.00 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $3,432.00 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $1,287.00 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $112.79 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $64.41 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $17.69 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $223.75 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $134.32 | General |
| Category: ONCOLOGY | ||||||
| 06/28/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $261.48 | General |
| Category: ONCOLOGY | ||||||
| 06/28/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $35.25 | General |
| Category: ONCOLOGY | ||||||
| 03/07/2024 | Mallinckrodt Hospital Products Inc. | CELLEX (Device) | Consulting Fee | Cash or cash equivalent | $3,140.00 | General |
| Category: CRITICAL CARE | ||||||
| 03/07/2024 | Mallinckrodt Hospital Products Inc. | CELLEX (Device) | Consulting Fee | Cash or cash equivalent | $785.00 | General |
| Category: CRITICAL CARE | ||||||
| 03/07/2024 | Mallinckrodt Hospital Products Inc. | CELLEX (Device) | Consulting Fee | Cash or cash equivalent | $785.00 | General |
| Category: CRITICAL CARE | ||||||
| 01/15/2024 | Partner Therapeutics, Inc. | LEUKINE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $365.25 | General |
| Category: Hematology/Oncology | ||||||
| 11/09/2023 | Mallinckrodt Hospital Products Inc. | — | Consulting Fee | Cash or cash equivalent | $392.50 | General |
| 12/21/2022 | Genentech, Inc. | OCREVUS (Biological) | Consulting Fee | Cash or cash equivalent | $2,817.50 | General |
| Category: Immunology | ||||||
| 11/01/2022 | PFIZER INC. | PAXLOVID (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: COVID19 HOSP CLINICAL PUBLICATION PROGRAM • Category: INFECTIOUS DISEASES | ||||||
| 07/26/2022 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,225.00 | General |
| 02/22/2022 | Partner Therapeutics, Inc. | Leukine (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $95.09 | General |
| Category: Hematology/Oncology | ||||||
| 12/15/2021 | Mallinckrodt Hospital Products Inc. | CELLEX (Device) | Consulting Fee | Cash or cash equivalent | $2,860.00 | General |
| Category: CRITICAL CARE | ||||||
| 11/24/2021 | Eli Lilly and Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| 10/21/2021 | Partner Therapeutics, Inc. | Leukine (Drug) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: Hematology/Oncology | ||||||
| 09/29/2021 | Partner Therapeutics, Inc. | Leukine (Drug) | Consulting Fee | Cash or cash equivalent | $875.00 | General |
| Category: Hematology/Oncology | ||||||
| 09/17/2020 | Partner Therapeutics, Inc. | Leukine (Drug) | Consulting Fee | Cash or cash equivalent | $875.00 | General |
| Category: Hematology | ||||||
| 02/26/2020 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| COVID19 HOSP CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 323 | 384 | $244,294 | $32,233 |
| 2022 | 9 | 304 | 361 | $220,715 | $29,190 |
| 2021 | 9 | 290 | 331 | $243,794 | $34,064 |
| 2020 | 9 | 260 | 279 | $201,427 | $31,192 |
Total Patients
1,177
Total Services
1,355
Medicare Billing
$126,678
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 73 | 114 | $50,306 | $9,137 | 18.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 45 | 49 | $64,337 | $5,115 | 8.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 35 | 35 | $28,175 | $5,023 | 17.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 16 | 17 | $23,766 | $3,782 | 15.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 28 | 28 | $21,376 | $3,279 | 15.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 19 | 21 | $23,121 | $2,402 | 10.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 20 | 20 | $10,980 | $2,152 | 19.6% |
| 45331 | Biopsy of lower large bowel using a flexible endoscope | Facility | 2023 | 24 | 27 | $17,712 | $1,017 | 5.7% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2023 | 63 | 73 | $4,521 | $325.12 | 7.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 52 | 69 | $30,495 | $5,736 | 18.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 45 | 53 | $69,589 | $4,938 | 7.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 24 | 24 | $18,952 | $4,021 | 21.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 18 | 18 | $23,685 | $3,901 | 16.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 28 | 33 | $17,490 | $3,092 | 17.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 20 | 20 | $20,932 | $2,614 | 12.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 17 | 17 | $12,741 | $2,132 | 16.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 16 | 27 | $7,641 | $1,632 | 21.4% |
| 45331 | Biopsy of lower large bowel using a flexible endoscope | Facility | 2022 | 17 | 22 | $14,432 | $765.73 | 5.3% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2022 | 67 | 78 | $4,758 | $357.85 | 7.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 45 | 75 | $35,925 | $7,956 | 22.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 45 | 45 | $36,657 | $7,800 | 21.3% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 52 | 57 | $74,841 | $5,305 | 7.1% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 24 | 25 | $41,025 | $3,933 | 9.6% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 17 | 17 | $23,561 | $3,797 | 16.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 15 | 15 | $13,149 | $2,804 | 21.3% |
About Michael Dougan, MD, PHD
Michael Dougan, MD, PHD is a Gastroenterology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2011. The National Provider Identifier (NPI) number assigned to this provider is 1225322258.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Michael Dougan, MD, PHD has received a total of $35,322 in payments from pharmaceutical and medical device companies, with $14,934 received in 2024. These payments were reported across 33 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($28,614).
As a Medicare-enrolled provider, Dougan has provided services to 1,177 Medicare beneficiaries, totaling 1,355 services with total Medicare billing of $126,678. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Boston, MA
- Active Since 06/07/2011
- Last Updated 11/22/2016
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1225322258
Products in Payments
- LIBTAYO (Biological) $9,859
- CELLEX (Device) $7,570
- Leukine (Drug) $4,645
- Actemra (Biological) $3,598
- PAXLOVID (Drug) $3,200
- OCREVUS (Biological) $2,818
- LEUKINE (Drug) $365.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Boston
Dr. Hiroyuki Aihara, M.d, M.D
Gastroenterology — Payments: $1.0M
Gastroenterology $1.0M
Dr. Ramnik Xavier, Md, MD
Gastroenterology — Payments: $518,235
Gastroenterology $518,235
Adam Cheifetz, M.d, M.D
Gastroenterology — Payments: $435,150
Gastroenterology $435,150
Fredric Gordon, M.d, M.D
Gastroenterology — Payments: $280,379
Gastroenterology $280,379
Dr. Tyler Berzin, Md, MD
Gastroenterology — Payments: $230,903
Gastroenterology $230,903
Dr. Douglas Pleskow, M.d, M.D
Gastroenterology — Payments: $170,196
Gastroenterology $170,196